Skip to main content

Branded

  • Novartis' Heart Partner app integrated into Walgreens Balance Rewards

    DEERFIELD, Ill. - Walgreens on Monday announced the integration of Novartis' Heart Partner app to its Balance Rewards for Health Choices API.

    "For [heart failure] patients it is sometimes difficult to keep up with a healthier lifestyle and managing their treatment," Walgreens developer evangelist Drew Schweinfurth posted in a blog. "The newly developed Heart Partner app helps coordinate care in a simple and easy way.  The app allows for tracking daily activity and vitals such as blood pressure or weight [and] medication compliance."

  • FDA approves Propeller platform for use with GSK’s Ellipta

     MADISON, Wis. — The Food and Drug Administration has cleared Propeller Health’s Propeller platform — a leading digital solution for respiratory medicine — to be used with GSK’s Ellipta, its dry powder inhaler. 
     
  • Female Health Company completes Aspen Park merger, rebrands as Veru Healthcare

    CHICAGO - The Female Health Company on Monday announced that it has successfully completed a transformational merger with Aspen Park Pharmaceuticals under modified terms. The combined company brings together FHC’s existing FC2 Female Condom product with APP’s extensive drug development portfolio of products.

    The combined company will be organized as follows: Veru Healthcare will manage the Pharmaceuticals and Medical Devices and Consumer Health divisions and The Female Health Company will manage the global Public Health sector FC2 business.

  • Aralez completes acquisition of U.S. rights to Toprol-XL, authorized generic

    MISSISSAUGA, Ontario — Specialty pharmacy company Aralez Pharmaceuticals on Monday announced the completion of its acquisition of the U.S. rights to AstraZeneca’s extended-release beta blocker, Toprol-XL (metoprolol succinate) and its authorized generic. Aralez paid $175 million at closing. 
     
  • London Drugs to donate UNICEF Canada vaccination for every flu shot given

    RICHMOND, British Columbia - Customers who receive their 2016/2017 influenza vaccination at London Drugs will now play an active role in helping to protect tens of thousands of the world's most vulnerable children from vaccine-preventable diseases, the Canadian retailer announced Monday. Through a new partnership with I Boost Immunity, a Canadian-based online immunization advocacy network, for every flu shot administered at London Drugs this year, a vaccine will be donated to UNICEF Canada to immunize children in a developing country.

  • Astellas to acquire Ganymed

    TOKYO and MAINZ, Germany — In a move that would expand its oncology pipeline, Astellas Pharma announced Friday its agreement to acquire Ganymed Pharmaceuticals for €422 million, or about $461 million. 
     
    Under the agreement, Astellas would acquire 100% of the equity in Ganymed and Ganymed shareholders will be able to receive up to €860 million in further contingent payments tied to the progress of Ganymed’s most advanced clinical program, IMAB362. Ganymed would become a wholly owned subsidiary of Astellas. 
X
This ad will auto-close in 10 seconds